OLYSIO(TM), in combination with peginterferon
alfa and ribavirin may cause birth defects or death of your unborn baby.
Pegylated interferon beta compounds in development as therapies for RMS include peginterferon
beta-1a (Biogen Idec, Inc.
INCIVO (telaprevir), in combination with peginterferon
alfa and ribavirin, is indicated for the treatment of genotype-1 chronic HCV in adult patients with compensated liver disease (including cirrhosis) who are treatment naE[macron]ve, and who have previously been treated with interferon alfa (pegylated or non pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.
Treatment started 2 weeks before peginterferon
therapy and continued for the 24-week regimen.
Even if we have a new drug of 2 in several years, peginterferon
will most likely have to included as part of the regimen.
Results showed that peginterferon
beta-1a also met the secondary endpoints of risk of 12-week confirmed disability progression, proportion of patients who relapsed and magnetic resonance imaging (MRI) assessments for both dose regimens.
The efficacy of OLYSIO in combination with peginterferon
and ribavirin is greatly decreased in patients who have genotype 1a Q80K.
Telaprevir has already halved the treatment duration for the majority of people with hepatitis C whilst significantly improving cure rates, compared to previous standard of care, peginterferon
alfa and ribavirin (PR).
Researchers have shown that treatment with peginterferon
alpha-2a (PegIFNa2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon
alpha-2b (PegIFNa2b) plus RBV.
BOSTON -- Combination therapy with peginterferon
[alpha]-2b and weight-based ribavirin produces consistent rates of sustained virologic response in obese patients with chronic hepatitis C virus, according to data from the largest hepatitis C virus study ever conducted in the United States.
The clinical trial will compare the triple combination therapy of Zadaxin, peginterferon
alfa-2a and ribavirin to placebo, peginterferon
alfa-2a and rebavirin to evaluate the benefit of adding Zadaxin to current therapy for hepatitis C patients who have failed to respond to previous treatment.
On November 14 the Antiviral Drugs Advisory Committee will review the application by Hoffmann-La Roche for approval of peginterferon
alfa-2a combined with ribavirin.